A reader asks: "What is the difference between progression-free survival rates for HER2-positive breast cancer patients on trastuzumab emtansine versus trastuzumab deruxtecan in third-line settings?"
This is a precise and critical question for patients and oncologists navigating later stages of metastatic HER2-positive breast cancer. The answer isn't a simple number; it's a story of evolving standards of care, driven by head-to-head clinical trial data. From what the latest evidence shows, trastuzumab deruxtecan (T-DXd, Enhertu) has largely redefined expectations for progression-free survival (PFS) in this setting compared to the former standard, trastuzumab emtansine (T-DM1, Kadcyla).
First, some context. In metastatic HER2+ breast cancer, treatment is sequenced. Initial lines typically involve combinations of HER2-targeted therapies like trastuzumab, pertuzumab, and taxane chemotherapy. When the disease progresses, the traditional next step was T-DM1, an antibody-drug conjugate (ADC) that delivers a chemotherapy agent directly to HER2-positive cells. For years, it was the established second-line therapy.
However, the landscape shifted with the development of T-DXd, a newer ADC with a different design. T-DXd carries a more potent chemotherapy payload and has a unique "bystander effect," meaning it can affect cancer cells near the targeted cell, which can be advantageous in tumors with mixed HER2 expression. The definitive answer to the reader's question comes from the phase 3 DESTINY-Breast03 trial.
While this trial primarily compared T-DXd to T-DM1 in the second-line setting, its results are directly relevant to the third-line question. Here's why: a patient receiving T-DM1 in the second line who progresses is, by definition, moving into third-line treatment. The DESTINY-Breast03 trial demonstrated that using T-DXd earlier (second line) dramatically outperformed T-DM1. The median progression-free survival for T-DXd was not reached at the time of analysis, while it was 6.8 months for T-DM1. The hazard ratio was 0.28, indicating a 72% reduction in the risk of disease progression or death with T-DXd.
Consequently, T-DXd became the new second-line standard. This means that in current practice, a patient reaching for a third-line therapy has likely already received T-DXd. If they have not, and T-DM1 is being considered as a third-line option, the expected PFS would align with the older, more modest benchmarks from the era before T-DXd—often in the range of 6-9 months, depending on prior treatments and patient factors. In most cases now, the comparison in the third-line setting is between T-DXd (if not used earlier) and other options like tucatinib combinations or novel agents in clinical trials.
The most important nuance here is that "line of therapy" is a clinical construct that changes as evidence evolves. A drug's performance is intrinsically tied to when in a patient's journey it is used. T-DM1 showed strong efficacy when it was tested in patients who had progressed on trastuzumab and a taxane (i.e., first-line therapy). Its PFS benefit was clear compared to the physician's choice of treatment at that time.
The counterintuitive reality is that a drug's published "third-line" PFS rate can become almost obsolete if that drug gets promoted to an earlier line due to superior data. This is exactly what happened. T-DXd's profound efficacy in second-line studies means it is rarely available as a third-line option in modern treatment algorithms. Therefore, comparing the two drugs head-to-head in a theoretical third-line scenario is less practical. The more relevant contemporary question is: after T-DXd (in second line), what provides the best PFS in third line? Current data points to regimens like tucatinib + capecitabine + trastuzumab, which in the HER2CLIMB trial showed a median PFS of 7.8 months in a heavily pre-treated population that included about half who had prior T-DM1.
This rapid evolution underscores why managing metastatic HER2+ breast cancer requires continuous access to the latest real-world outcomes and clinical trial data. For oncology teams, synthesizing this information is key to sequencing therapies effectively. Some practices utilize specialized oncology data services to track these shifting paradigms and outcomes in real-time, ensuring treatment plans reflect the current standard rather than historical benchmarks.
Direct head-to-head data in the third-line setting between T-DM1 and T-DXd doesn't exist in a vacuum, because T-DXd's superiority has moved it to an earlier line of therapy. Based on the pivotal DESTINY-Breast03 trial, T-DXd provides a significantly longer progression-free survival compared to T-DM1—so much so that it has replaced T-DM1 as the standard second-line treatment. Therefore, a patient in the third-line today would likely have already received T-DXd. If considering T-DM1 as a later-line option after other treatments, expected PFS would be closer to the 6-8 month range observed in earlier studies. The central takeaway is that the therapeutic sequence for HER2+ metastatic breast cancer is dynamic, with PFS expectations for any given drug heavily dependent on its position in the ever-changing treatment hierarchy.